In the new high-throughput screening (HTS) campaign, receptor functional assays, 3’,5’-cyclic adenosine mono-phosphate (cAMP), intracellular [Ca2+]i, phosphatidylinositol turnover, and reporter-based assays are being used as primary screens as they are now developed as homogeneous and automation-friendly assays. FlashPlate assay and scintillation proximity assay using radiolabeled cAMP have been used for measuring cAMP. A nonradioactive homogeneous HTS assay using HitHunter™ enzyme fragment complementation (EFC) technology was evaluated for measuring cAMP in adherent and suspension cells overexpressing a Gαs-coupled receptor. In the EFC-cAMP assay, the β-galactosidase (β-gal) donor fragment-cAMP (ED-cAMP) conjugate complements with the β-gal enzyme acceptor (EA) fragment to form an active β-gal enzyme. Binding of ED-cAMP conjugate to the anti-cAMP antibody prevents its complementation with the EA fragment to form an active enzyme. Cyclic AMP in the samples compete with ED-cAMP to bind to the anti-cAMP antibody, thus increasing the free ED-cAMP that can complement with the EA fragment to form an active enzyme that is assayed with a luminescent substrate. Thus, this assay results in a positive signal unlike other technologies, wherein the signal is completed by cAMP in the sample. Glucagon-like peptide (GLP)-1 binds to GLP-1 receptor (with a Kd of 0.2 nM) signals through Gαs to activate adenylate cyclase, which results in an increase of intracellular cAMP (EC50 of 0.3 nM). GLP-1 stimulation of cAMP levels measured by the EFC method was similar in both adherent and suspension cell formats (EC50 ~0.3 nM) at different cell numbers. The assay was further validated with forskolin, exendin, and several active GLP-1 peptide analogues. The stimulation of cAMP by GLP-1 and forskolin was effectively inhibited by the adenylate cyclase inhibitors MDL-12330A and SQ-22536, confirming that the increased cAMP is through the AC pathway. The assay tolerates dimethyl sulfoxide (DMSO) up to 10%, and tartrazine does not interfere with the assay with the adherent cells up to 1 mM and affects minimally up to 10 μM in suspension cells. The assay is very robust, with a Z value of 0.7 to 0.8. The assay was validated with several plates of low molecular weight nonpeptide compounds and peptide agonists with different potencies. The suspension cell protocol is a robust homogeneous assay that involves fewer steps than the adherent cell protocol and is suitable for HTS. The cAMP assay using EFC technology is advantageous in that it has a greater dynamic range of detection; is nonradioactive, very sensitive, robust; has minimal interference from DMSO and colored compounds; and is amenable for automation. An added advantage of this assay is that the cAMP is measured as a positive signal, thereby reducing the incidence of false positives.
References
1.
1. Seethala R: Receptor screens for small molecule agonist and antagonist discovery. In Seethala R, Fernandes P (eds): Handbook of Drug Screening. New York: Marcel Dekker, 2001:189-264.
2.
2. Hamm HE: The many faces of G protein signaling. J Biol Chem1988;273:669-672.
3.
3. Gilman AG: G-proteins and regulation of adenyl cyclase. JAMA1989;262:1819-1825.
4.
4. Wise A, Geaing K, Rees S: Target validation of G-protein coupled receptors. Drug Discov Today2002;7:235-246.
5.
5. Krishna G, Weiss B, Brodie BB: A simple sensitive method for the assay of adenyl cyclase. J Pharmacol Exp Ther1968;163:379-385.
6.
6. Ramachandran J: A new simple method of separation of adenosine 3’,5’-cyclic monophosphate from other nucleotides and its use in the assay of adenyl cyclase. Anal Biochem1971;43:227-239.
7.
7. Alexander SPH: The measurement of cyclic AMP levels in biological preparations. Meth Mol Biol1995;41:79-89.
8.
8. Horton JK, Baxendale PM: Mass measurements of cyclic AMP formation by radioimmunoassay, enzyme immunoassay and scintillation proximity assay. Meth Mol Biol1995;41:91-112.
9.
9. Kariv I, Stevens ME, Behrens DL, Oldenburg KR: High throughput quantitation of cAMP production mediated by activation of seven transmembrane domain receptors. J Biomol Screen1999;4:27-32.
10.
10. Orskov C: Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia1992;35:701-711.
11.
11. Byrne MM, Goke B: Human studies with glucagon-like peptide-1: potential of the gut hormone for clinical use. Diabetic Medicine1996;13:854-860.
12.
12. Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, et al: A role of glucagon-like peptide-1 in the central regulation of feeding. Nature1996;379:69-72.
13.
13. Kim A, Brit HB, Liselotte KB, Ole K: Structure-activity studies of glucagon-like peptide-1. J Biol Chem1994;269:6275-6278.
14.
14. Remy I, Michnick SW: Clonal selection and in vivo quantitation of protein-protein interactions with protein-fragment complementation assays. Proc Natl Acad Sci USA1999;96:5394-5399.
15.
15. Pelletier JN, Arndt KM, Pluckthun A, Michnick SW: An in vivo library-versus-library selection of optimized protein-protein interactions. Nature Biotech1999;17:683-690.
16.
16. Rossi F, Charlton CA, Blau HM: Monitoring protein-protein interactions in intact eukaryotic cells by β-galactosidase complementation. Proc Natl Acad Sci USA1997;94:8405-8410.
17.
17. Zhang J-H, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen1999;4:67-73.
